RxDoctor Payments Data

M Jacqueline Tarsitano, MD

Internal Medicine · Anchorage, AKNPI 1669853347

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 57.7% of the total. Reporting peaked in 2019 at $229 and has fallen 85.4% since, to $33 in 2024.

$406in general payments, 2019–2025

Across 7 payments — averaging $58.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$235
  • Pfizer$116
  • Intuitive Surgical$33
  • QOL Medical, LLC$22

What the payments were for

  • Food & beverage$406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$406 in reported general payments places this provider in the 70th percentile of 124 internal medicine providers in Alaska.

See all internal medicine providers in Alaska

Medicare billing

Part B allowed, 2024
$356,636
Medicare patients
673
Services billed
4,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin98$145,916
MounjaroTirzepatide69$99,672
OzempicSemaglutide59$98,232
TrulicityDulaglutide55$84,439
EliquisApixaban35$50,982
GemtesaVibegron24$34,350
RybelsusSemaglutide13$22,574
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,654
Repatha SureclickEvolocumab18$19,478
Combivent RespimatIpratropium/Albuterol Sulfate16$16,228
MyrbetriqMirabegron11$13,786
JanuviaSitagliptin Phosphate20$13,456
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$10,558
Tresiba Flextouch U-100Insulin Degludec13$9,406
Rosuvastatin Calcium423$7,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$116$56,77848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 124 internal medicine providers in Alaska.

Other internal medicine in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →